Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints

被引:2
|
作者
Martinez, Jordi Cortes [1 ]
Geskus, Ronald B. [2 ,3 ]
Kim, Kyung Mann [4 ]
Melis, Guadalupe Gomez [1 ]
机构
[1] Univ Politecn Cataluna, Dept Stat & Operat Res, Jordi Girona 31, Barcelona 08034, Spain
[2] Univ Oxford, Clin Res Unit, Ho Chi Minh City, Vietnam
[3] Ctr Trop Med & Global Hlth, Nuffield Dept Med, Oxford, England
[4] Univ Wisconsin, Dept Biostat & Med Informat, 600 Highland Ave, Madison, WI 53792 USA
基金
英国惠康基金;
关键词
Treatment Effect; Composite endpoint; Randomized Controlled Trial; Progression-Free Survival; Simulation; Copula; Non-Proportional Hazards; DOUBLE-BLIND; SURVIVAL;
D O I
10.1186/s12874-021-01286-x
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background Sample size calculation is a key point in the design of a randomized controlled trial. With time-to-event outcomes, it's often based on the logrank test. We provide a sample size calculation method for a composite endpoint (CE) based on the geometric average hazard ratio (gAHR) in case the proportional hazards assumption can be assumed to hold for the components, but not for the CE. Methods The required number of events, sample size and power formulae are based on the non-centrality parameter of the logrank test under the alternative hypothesis which is a function of the gAHR. We use the web platform, CompARE, for the sample size computations. A simulation study evaluates the empirical power of the logrank test for the CE based on the sample size in terms of the gAHR. We consider different values of the component hazard ratios, the probabilities of observing the events in the control group and the degrees of association between the components. We illustrate the sample size computations using two published randomized controlled trials. Their primary CEs are, respectively, progression-free survival (time to progression of disease or death) and the composite of bacteriologically confirmed treatment failure or Staphylococcus aureus related death by 12 weeks. Results For a target power of 0.80, the simulation study provided mean (+/- SE) empirical powers equal to 0.799 (+/- 0.004) and 0.798 (+/- 0.004) in the exponential and non-exponential settings, respectively. The power was attained in more than 95% of the simulated scenarios and was always above 0.78, regardless of compliance with the proportional-hazard assumption. Conclusions The geometric average hazard ratio as an effect measure for a composite endpoint has a meaningful interpretation in the case of non-proportional hazards. Furthermore it is the natural effect measure when using the logrank test to compare the hazard rates of two groups and should be used instead of the standard hazard ratio.
引用
收藏
页数:14
相关论文
共 50 条
  • [1] Using the geometric average hazard ratio in sample size calculation for time-to-event data with composite endpoints
    Jordi Cortés Martínez
    Ronald B. Geskus
    KyungMann Kim
    Guadalupe Gómez Melis
    BMC Medical Research Methodology, 21
  • [2] Hazard ratio inference in stratified clinical trials with time-to-event endpoints and limited sample size
    Xu, Rengyi
    Mehrotra, Devan V.
    Shaw, Pamela A.
    PHARMACEUTICAL STATISTICS, 2019, 18 (03) : 366 - 376
  • [3] SOME ISSUES OF SAMPLE SIZE CALCULATION FOR TIME-TO-EVENT ENDPOINTS USING THE FREEDMAN AND SCHOENFELD FORMULAS
    Abel, Ulrich R.
    Jensen, Katrin
    Karapanagiotou-Schenkel, Irini
    Kieser, Meinhard
    JOURNAL OF BIOPHARMACEUTICAL STATISTICS, 2015, 25 (06) : 1285 - 1311
  • [4] The Average Hazard Ratio - A Good Effect Measure for Time-to-event Endpoints when the Proportional Hazard Assumption is Violated?
    Rauch, Geraldine
    Brannath, Werner
    Brueckner, Matthias
    Kieser, Meinhard
    METHODS OF INFORMATION IN MEDICINE, 2018, 57 (03) : 89 - 100
  • [5] Sample size calculation for mixture model based on geometric average hazard ratio and its applications to nonproportional hazard
    Wang, Zixing
    Zhang, Qingyang
    Xue, Allen
    Whitmore, James
    PHARMACEUTICAL STATISTICS, 2024, 23 (03) : 325 - 338
  • [6] Sample size calculation for time-to-event data in stepped wedge cluster randomised trials
    Takanashi, Fumihito
    Keding, Ada
    Crouch, Simon
    Kanaan, Mona
    TRIALS, 2016, 17
  • [7] Sample size calculation for cluster randomization trials with a time-to-event endpoint
    Li, Jianghao
    Jung, Sin-Ho
    STATISTICS IN MEDICINE, 2020, 39 (25) : 3608 - 3623
  • [8] BEATS: Bayesian hybrid design with flexible sample size adaptation for time-to-event endpoints
    Bi, Dehua
    Liu, Meizi
    Lin, Jianchang
    Liu, Rachael
    STATISTICS IN MEDICINE, 2023, 42 (30) : 5708 - 5722
  • [9] Imputation of Missing Data for Time-to-Event Endpoints Using Retrieved Dropouts
    Shuai Wang
    Robert Frederich
    James P. Mancuso
    Therapeutic Innovation & Regulatory Science, 2024, 58 : 114 - 126
  • [10] Sample size calculations for noninferiority trials for time-to-event data using the concept of proportional time
    Phadnis, Milind A.
    Mayo, Matthew S.
    JOURNAL OF APPLIED STATISTICS, 2021, 48 (06) : 1009 - 1032